Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Aerobic and Resistance Exercise Improves Shoulder Function in Women Who Are Overweight or Obese and Have Breast Cancer: A Randomized Controlled Trial.

Sweeney FC, Demark-Wahnefried W, Courneya KS, Sami N, Lee K, Tripathy D, Yamada K, Buchanan TA, Spicer DV, Bernstein L, Mortimer JE, Dieli-Conwright CM.

Phys Ther. 2019 Oct 28;99(10):1334-1345. doi: 10.1093/ptj/pzz096.

PMID:
31309977
2.

Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.

Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer DV, Tripathy D, Bernstein L, Mortimer JE.

J Clin Oncol. 2018 Mar 20;36(9):875-883. doi: 10.1200/JCO.2017.75.7526. Epub 2018 Jan 22.

3.

Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone.

Agarwal SK, Daniels A, Drosman SR, Udoff L, Foster WG, Pike MC, Spicer DV, Daniels JR.

Biomed Res Int. 2015;2015:934164. doi: 10.1155/2015/934164. Epub 2015 Dec 31.

4.

Biological effects of green tea capsule supplementation in pre-surgery postmenopausal breast cancer patients.

Yu SS, Spicer DV, Hawes D, Tseng CC, Yang CS, Pike MC, Wu AH.

Front Oncol. 2013 Dec 13;3:298. doi: 10.3389/fonc.2013.00298. eCollection 2013.

5.

Soy isoflavones for breast cancer risk reduction.

Wu AH, Spicer DV, Pike MC.

Cancer Prev Res (Phila). 2012 Jul;5(7):984-5; author reply 986-7. doi: 10.1158/1940-6207.CAPR-12-0102. Epub 2012 Jun 12. No abstract available.

6.

Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.

Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL.

Contraception. 2012 Sep;86(3):238-43. doi: 10.1016/j.contraception.2011.12.015. Epub 2012 Feb 9.

7.

Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.

Chung K, Hovanessian-Larsen LJ, Hawes D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL.

Breast Cancer Res Treat. 2012 Apr;132(2):653-60. doi: 10.1007/s10549-011-1870-y. Epub 2011 Nov 15.

8.

Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G.

J Clin Oncol. 2011 Nov 20;29(33):4373-80. doi: 10.1200/JCO.2010.33.6446. Epub 2011 Oct 17.

9.

Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast.

Taylor D, Pearce CL, Hovanessian-Larsen L, Downey S, Spicer DV, Bartow S, Pike MC, Wu AH, Hawes D.

Breast Cancer Res Treat. 2009 Nov;118(1):161-8. doi: 10.1007/s10549-009-0322-4. Epub 2009 Feb 10.

PMID:
19205874
10.

Estrogens, progestins, and risk of breast cancer.

Pike MC, Wu AH, Spicer DV, Lee S, Pearce CL.

Ernst Schering Found Symp Proc. 2007;(1):127-50. Review.

PMID:
18540571
11.

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.

Weitzel JN, Buys SS, Sherman WH, Daniels A, Ursin G, Daniels JR, MacDonald DJ, Blazer KR, Pike MC, Spicer DV.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):654-8.

12.

Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.

Gram IT, Ursin G, Spicer DV, Pike MC.

Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1117-20.

13.

Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists.

Spicer DV, Pike MC.

Breast Cancer Res. 2000;2(4):264-7. Epub 2000 May 24. Review.

14.

Mammographic density changes during the menstrual cycle.

Ursin G, Parisky YR, Pike MC, Spicer DV.

Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):141-2.

15.

Hormonal contraception and chemoprevention of female cancers.

Pike MC, Spicer DV.

Endocr Relat Cancer. 2000 Jun;7(2):73-83. Review.

PMID:
10903525
16.

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.

Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso LJ, Clendeninn NJ.

Cancer Chemother Pharmacol. 2000;45(5):423-7.

PMID:
10803927
17.

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.

Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R.

Cancer Chemother Pharmacol. 2000;45(2):103-10.

PMID:
10663624
18.
19.

The detection of changes in mammographic densities.

Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV.

Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):43-7. Erratum in: Cancer Epidemiol Biomarkers Prev 1998 Feb;7(2):174.

20.

Progesterone concentrations--physiologic or pharmacologic?

Spicer DV, Ursin G, Pike MC.

Fertil Steril. 1996 May;65(5):1077-8. No abstract available.

PMID:
8612843
21.

Experiments on proliferation of normal human breast tissue in nude mice do not show that progesterone does not stimulate breast cells.

Pike MC, Ursin G, Spicer DV.

Endocrinology. 1996 Apr;137(4):1505-6. No abstract available.

PMID:
8625931
22.

Can mammographic densities predict effects of tamoxifen on the breast?

Ursin G, Pike MC, Spicer DV, Porrath SA, Reitherman RW.

J Natl Cancer Inst. 1996 Jan 17;88(2):128-9. No abstract available.

PMID:
8537975
23.

Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.

Winer EP, Chu L, Spicer DV.

Semin Oncol. 1995 Apr;22(2 Suppl 5):72-8; discussion 78-9. Review.

PMID:
7740337
24.

Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.

Turrill M, Spicer DV, Kelley AS, Herman RL, Russell CA, Muggia FM.

Cancer Invest. 1995;13(2):160-4.

PMID:
7874569
25.

The endocrine prevention of breast cancer.

Spicer DV, Krecker EA, Pike MC.

Cancer Invest. 1995;13(5):495-504. Review.

PMID:
7552817
26.

Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.

Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC.

J Natl Cancer Inst. 1994 Mar 16;86(6):431-6.

PMID:
8120917
27.

Contraception and cancer prevention.

Ursin G, Spicer DV, Pike MC.

Adv Contracept Deliv Syst. 1994;10(3-4):369-86.

PMID:
12287845
28.

Sex steroids and breast cancer prevention.

Spicer DV, Pike MC.

J Natl Cancer Inst Monogr. 1994;(16):139-47. Review.

PMID:
7999456
29.

Breast cancer prevention through modulation of endogenous hormones.

Spicer DV, Pike MC.

Breast Cancer Res Treat. 1993 Nov;28(2):179-93. Review.

PMID:
8173070
30.

Hormone replacement after breast cancer.

Spicer DV, Pike MC.

Lancet. 1993 Jul 17;342(8864):183-4. No abstract available.

PMID:
8101287
31.

Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer.

Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J.

Contraception. 1993 May;47(5):427-44.

PMID:
8390340
32.

Tamoxifen and prevention.

Ursin G, Spicer DV, Pike MC.

Lancet. 1993 Mar 13;341(8846):693-4; author reply 695. No abstract available.

PMID:
8095598
33.

Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.

Pike MC, Spicer DV, Dahmoush L, Press MF.

Epidemiol Rev. 1993;15(1):17-35. Review.

PMID:
8405201
34.

The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology.

Pike MC, Spicer DV.

J Cell Biochem Suppl. 1993;17G:26-36. Review.

PMID:
8007706
35.

The prevention of breast cancer through reduced ovarian steroid exposure.

Spicer DV, Pike MC.

Acta Oncol. 1992;31(2):167-74. Review.

PMID:
1622631
36.

Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.

Spicer DV, Kelley A, Herman R, Dean G, Stevenson L, Mitchell MS.

Cancer Immunol Immunother. 1992;34(6):424-6.

PMID:
1532923
37.

GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer.

Spicer DV, Shoupe D, Pike MC.

Contraception. 1991 Sep;44(3):289-310. Review.

PMID:
1662596
38.

Ovarian cancer and long-term tamoxifen in premenopausal women.

Spicer DV, Pike MC, Henderson BE.

Lancet. 1991 Jun 8;337(8754):1414. No abstract available.

PMID:
1674785
39.

Tamoxifen and estrogen replacement therapy as agents of disease prevention.

Spicer DV, Pike MC, Henderson BE, Groshen S.

J Natl Cancer Inst. 1991 Jan 2;83(1):63-4. No abstract available.

PMID:
1984521
40.

Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.

Grunberg SM, Clay C, Spicer DV.

Sel Cancer Ther. 1991 Spring;7(1):17-21.

PMID:
1833803
41.

Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics.

Spicer DV, Ardalan B, Daniels JR, Silberman H, Johnson K.

Cancer Res. 1988 Jan 15;48(2):459-61.

Supplemental Content

Loading ...
Support Center